Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Clascoterone (Primary) ; Clascoterone (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Intrepid Therapeutics
- 29 May 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 12 May 2014 New trial record